A midpandemic night's dream: Melatonin, from harbinger of antiinflammation to mitochondrial savior in acute and long COVID19 (Review).
Int J Mol Med
; 53(3)2024 03.
Article
em En
| MEDLINE
| ID: mdl-38299237
ABSTRACT
Coronavirus disease 2019 (COVID19), a systemic illness caused by severe acute respiratory distress syndrome 2 (SARSCoV2), has triggered a worldwide pandemic with symptoms ranging from asymptomatic to chronic, affecting practically every organ. Melatonin, an ancient antioxidant found in all living organisms, has been suggested as a safe and effective therapeutic option for the treatment of SARSCoV2 infection due to its good safety characteristics and broadspectrum antiviral medication properties. Melatonin is essential in various metabolic pathways and governs physiological processes, such as the sleepwake cycle and circadian rhythms. It exhibits oncostatic, antiinflammatory, antioxidant and antiaging properties, exhibiting promise for use in the treatment of numerous disorders, including COVID19. The preventive and therapeutic effects of melatonin have been widely explored in a number of conditions and have been wellestablished in experimental ischemia/reperfusion investigations, particularly in coronary heart disease and stroke. Clinical research evaluating the use of melatonin in COVID19 has shown various improved outcomes, including reduced hospitalization durations; however, the trials are small. Melatonin can alleviate mitochondrial dysfunction in COVID19, improve immune cell function and provide antioxidant properties. However, its therapeutic potential remains underexplored due to funding limitations and thus further investigations are required.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
COVID-19
/
Melatonina
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article